AbbVie's Allergan Aesthetics has secured European approval for Boey (trenibotulinumtoxinE), a rapid-onset, short-duration neurotoxin indicated for glabellar frown lines. Boey's differentiation lies in onset speed and duration profile—a distinct clinical positioning versus Botox (onset 3–7 days, duration 12+ weeks) and Dysport (faster onset, variable duration).
Injectables
Allergan Aesthetics Wins EU Approval for Boey — First Rapid-Onset, Short-Duration Neurotoxin Reshapes Toxin Economics
Boey (trenibotulinumtoxinE) becomes the first rapid-onset, short-duration neuromodulator approved in Europe, fragmenting the toxin market.
1-YEAR MOVE
ABBV
▲11.6%
EOLS
▼15.6%
| Ticker | Company | 1-year change |
|---|---|---|
| ABBV | AbbVie (Allergan Aesthetics) | +11.6% |
| EOLS | Evolus | −15.6% |